论文部分内容阅读
目的 :评价金蒲抑瘤片治疗气滞血瘀证之原发性肝癌的疗效和毒副反应。方法 :病例随机分为治疗组和对照组 :治疗组 :2 0 0例 ,口服金蒲抑瘤片 ,每天 3次 ,每次 5片 ,治疗≥ 4周 ,联合常规经肝动脉化疗栓塞、放疗治疗 ;对照组 :10 0例 ,常规经肝动脉化疗栓塞、放疗治疗。一个月后评价症状改善、肿瘤大小的变化 ,以及药物的毒副反应。结果 :治疗组病例的临床症状改善总有效率 (84% )高于对照组 (6 5 % ) ;治疗组癌灶总有效率 (CR+ PR+ NC)为 83% ,亦高于对照组(6 4% ) ;毒副反应低。结论 :金蒲抑瘤片对原发性肝癌的化学和放射治疗具有增效作用。
Objective: To evaluate the efficacy and toxicity of Jinpu Xiaoliu Tablet in the treatment of primary liver cancer with qi stagnation and blood stasis syndrome. Methods: Cases were randomly divided into treatment group and control group: treatment group: 200 cases, oral Jinpu anti-tumor tablets, 3 times a day, 5 tablets each time, treatment for ≥ 4 weeks, combined with conventional transcatheter arterial chemoembolization, radiotherapy Treatment; Control group: 100 cases, routine transcatheter arterial chemoembolization, radiotherapy. After one month, the improvement of symptoms, changes in tumor size, and toxicity of the drug were evaluated. Results: The total effective rate of improvement of clinical symptoms in the treatment group (84%) was higher than that in the control group (65%); the total effective rate of the cancer in the treatment group (CR+PR+ NC) was 83%, which was also higher than that in the control group (6 4 %). The toxicity is low. Conclusion : Jinpu Xiaoliu Tablet has synergistic effect on chemotherapy and radiotherapy of primary liver cancer.